Stocks › KURA
Kura Oncology, Inc.
KURA·Nasdaq·
United States·USD
United States·USD$10.53
-0.09 (-0.85%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
KURA
Kura Oncology, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
KURAS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of KURA by members of U.S. Congress · 1 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Christopher L. JacobsHouse · R · NY |
KURAKura Oncology, Inc. · Stock |
Purchase $1,001 - $15,000 |
Jan 20, 2023 | Dec 12, 2022 | Filing ↗ |
Whale Activity
Position changes in KURA reported for 2026-06-30 by 9 tracked institutional filers
- Increased4
- New0
- Held0
- Decreased3
- Closed0
- No prior filing2
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 10.5M | $115.3M | increased |
| BVF INC/IL | 8.4M | $92.7M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.9M | $43.0M | increased |
| RENAISSANCE TECHNOLOGIES LLC | 1.7M | $18.3M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.3M | $14.6M | increased |
| MILLENNIUM MANAGEMENT LLC | 711.3K | $7.8M | decreased |
| CITADEL ADVISORS LLC | 328.1K | $3.6M | decreased |
| TWO SIGMA INVESTMENTS, LP | 167.6K | $1.8M | decreased |
| Knott David M Jr | 52.8K | $579K | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by KURA insiders, by quarter · Form 4
Recent Insider Transactions
223 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| FORD KATHLEENChief Operating Officer | Sale | −3,668 | $10.75 | $39K | Sep 29, 2026 | Form 4 ↗ |
| Leoni MollieChief Medical Officer | Sale | −28.8K | $10.75 | $310K | Sep 29, 2026 | Form 4 ↗ |
| Powl Brian T.Chief Commercial Officer | Sale | −15.4K | $10.75 | $166K | Sep 29, 2026 | Form 4 ↗ |
| Bair Teresa BrophyChief Legal Officer | Sale | −8,442 | $10.50 | $89K | Sep 28, 2026 | Form 4 ↗ |
| FORD KATHLEENChief Operating Officer | Sale | −6,906 | $10.50 | $72K | Sep 28, 2026 | Form 4 ↗ |
| Leoni MollieChief Medical Officer | Sale | −12.4K | $10.50 | $131K | Sep 28, 2026 | Form 4 ↗ |
| DOYLE THOMAS JAMESSVP, Finance & Accounting | Sale | −4,607 | $10.50 | $48K | Sep 28, 2026 | Form 4 ↗ |
| Powl Brian T.Chief Commercial Officer | Sale | −9,020 | $10.50 | $95K | Sep 28, 2026 | Form 4 ↗ |
| Powl Brian T.Chief Commercial Officer | Sale | −8,000 | $10.56 | $84K | Sep 28, 2026 | Form 4 ↗ |
| Burrows FrancisChief Scientific Officer | Sale | −20.7K | $10.83 | $225K | Sep 24, 2026 | Form 4 ↗ |
| WILSON TROY EDWARDPresident and CEO · Director | Purchase | +100.0K | $12.39 | $1.2M | Aug 24, 2026 | Form 4 ↗ |
| Powl Brian T.Chief Commercial Officer | Sale | −4,345 | $11.89 | $52K | Aug 21, 2026 | Form 4 ↗ |
| Bair Teresa BrophyChief Legal Officer | Sale | −31.5K | $12.63 | $398K | Aug 19, 2026 | Form 4 ↗ |
| WILSON TROY EDWARDPresident and CEO · Director | Purchase | +100.0K | $11.12 | $1.1M | Aug 17, 2026 | Form 4 ↗ |
| Leoni MollieChief Medical Officer | Sale | −84.9K | $9.82 | $834K | Jun 18, 2026 | Form 4 ↗ |
| Powl Brian T.Chief Commercial Officer | Sale | −10.0K | $11.00 | $110K | May 21, 2026 | Form 4 ↗ |
| FORD KATHLEENChief Operating Officer | Sale | −2,257 | $9.08 | $20K | May 19, 2026 | Form 4 ↗ |
| Powl Brian T.Chief Commercial Officer | Sale | −339 | $9.21 | $3K | May 19, 2026 | Form 4 ↗ |
| Bair Teresa BrophyChief Legal Officer | Sale | −2,256 | $9.38 | $21K | May 18, 2026 | Form 4 ↗ |
| WILSON TROY EDWARDPresident and CEO · Director | Option exercise | +6,103 | $6.15 | $38K | Mar 23, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding KURA · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 3.1M | $34.1M | 0.32% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 2.8M | $30.7M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 2.2M | $24.3M | 0.03% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.0M | $11.3M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF iShares Trust | 785.1K | $8.6M | 0.06% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 929.0K | $8.4M | 0.02% | Jul 31, 2026 |
| iShares Biotechnology ETF iShares Trust | 606.1K | $6.6M | 0.07% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund BlackRock Funds | 565.0K | $5.8M | 0.11% | May 29, 2026 |
| iShares Russell 2000 Value ETF iSHARES TRUST | 691.8K | $5.6M | 0.05% | Mar 31, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 451.5K | $4.6M | 0.01% | May 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list KURA's shares (CUSIP 50127T109), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Aaron CowenSCHEDULE 13G/A · passive (13G) · 8.6M shares9.7%
Aug 14, 2026 · ↗ - Averill Master Fund, Ltd.SCHEDULE 13G/A · passive (13G) · 7.8M shares8.8%
Aug 14, 2026 · ↗ - Montanova Capital, LLCSCHEDULE 13G/A · passive (13G) · 8.6M shares9.7%
Aug 14, 2026 · ↗ - Steven BoydSCHEDULE 13G/A · passive (13G) · 3.7M shares4.2%
May 15, 2026 · ↗ - Armistice Capital, LLCSCHEDULE 13G/A · passive (13G) · 3.7M shares4.2%
May 15, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming Kura Oncology, Inc. as client
No lobbying filings found naming Kura Oncology, Inc. as the client.
Government Contracts
Federal awards to Kura Oncology, Inc. · USAspending
No federal contract awards found for Kura Oncology, Inc..
U.S. Patents
Recent USPTO applications naming Kura Oncology, Inc.
No USPTO patent applications found for Kura Oncology, Inc..
Annual Financials
From KURA's 10-K filings · XBRL
No annual XBRL figures on record for KURA. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in KURA's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 8.01Other eventsSep 9, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeSep 8, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 12, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeJul 29, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 4, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 12, 2026
EDGAR ↗
About Kura Oncology, Inc.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersSAN DIEGO, CA
IncorporatedDE
SEC CIK0001422143 ↗
Former namesZETA ACQUISITION CORP III